Plain-English translation of NCT06680037 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment called for people with certain autoimmune diseases—conditions where the immune system mistakenly attacks the body. The treatment uses modified cells to help calm down the overactive immune response. Researchers want to find the safest and most effective dose of this medication before testing it more widely.
Current treatments for these autoimmune diseases don't work well enough for everyone, and some people continue to get worse despite treatment. This trial is exploring whether this new cell-based approach could offer a better option for people whose conditions aren't adequately controlled by standard therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will receive a single intravenous infusion of the study medication on Day 0 (the first treatment day). Before the infusion, you will undergo a conditioning treatment to prepare your body. The study team will then monitor you closely after the infusion to watch for any side effects and to see how your body responds to the treatment. You'll have follow-up visits and tests to track your health over time.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States